AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03842332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills and Resilience Program
Description: The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
Study NCT02413138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan (VRS-317)
Description: Long acting recombinant human growth hormone
Study NCT02941549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT02941549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epeleuton
Study NCT03580551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status.
Study NCT03580551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control Group
Description: At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment.
Study NCT03646266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Titration with rocuronium bromide until tidal volume 6ml/kg PBW
Study NCT03955926 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative oral carbohydrate loading
Description: Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
Study NCT02168998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clown
Description: Comparison of routine venipuncture with a distraction technique by a medical clown
Study NCT04121715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fastigial Nucleus Stimulation
Description: Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
Study NCT04121715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Study NCT04121715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Study NCT01685268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
Study NCT01685268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 mg PO daily.
Study NCT01685268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO twice daily.
Study NCT03408028 — intervention group
Intervention type: OTHER
Intervention: Medical File consultation
Description: Medical File consultation
Study NCT03087318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months.
Study NCT00916760 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous monthly treatment
Study NCT02976987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Study NCT06606145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous Anastomosis
Description: LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.
Study NCT06606145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer
Description: VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.
Study NCT06606145 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer
Description: Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.
Study NCT06606145 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complex Decongestive Therapy
Description: The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
Study NCT01793337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to cold environmental temperature (-20°C)
Study NCT03209557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmartWatch SmokeBeat Application
Description: The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
Study NCT06163313 — intervention group
Intervention type: OTHER
Intervention: Observation of patients suffering from kidney stones who undergo endoscopic surgery
Description: Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
Study NCT01877070 — intervention group
Intervention type: BEHAVIORAL
Intervention: assessments
Study NCT02852785 — intervention group
Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
Study NCT00025259 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bleomycin Sulfate
Description: Given IV or SC
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02852785 — intervention group
Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
Study NCT00705406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir
Description: 600 mg peramivir administered as bilateral 2-mL intramuscular injection
Study NCT00705406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
Study NCT00025259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03472352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: An anticancer medication (A01) and immune cells (IC01)
Description: The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
Study NCT04031365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Use of sterile, disposable needles in acupuncture
Study NCT04031365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: psychotherapy
Study NCT04031365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: psychotherapy
Study NCT02966652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DITEST
Description: Lipid formulation of native oral testosterone.
Study NCT02966652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DITEST
Description: Lipid formulation of native oral testosterone.
Study NCT02966652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate
Description: Generic treatment for patients with primary or secondary male hypogonadism
Study NCT03844685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promensil
Description: 1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
Study NCT03844685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet (80 mg) (without active principle) given once a day for 24 months
Study NCT01584466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary.
Study NCT03213028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: WHO Decision-Making Tool for Family Planning Clients and Providers
Description: Contraception decision-making tool
Study NCT02434276 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
Study NCT02434276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Fluzone Quadrivalent (Influenza Vaccine)
Study NCT00442104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Study NCT01883193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comprehensive Maternal Nutrition Intervention
Description: The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
Study NCT02852785 — intervention group
Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
Study NCT04239768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MonoDermà HA gel combined to a low level laser
Description: Two intradermal injections of the filler were performed during the basal and after 1 month, on the middle and inferior third of the face (1ml for each face side) using a needle (30G).~Immediately after both injection procedures, LLLT session were performed on the same face area for a total of 8 minutes, using three different wavelengths (450 nm, 650 nm and 1064 nm) simultaneously.
Study NCT02852785 — intervention group
Intervention type: BEHAVIORAL
Intervention: PNF D2 for extension; moderate-to-high loading condition
Description: Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
Study NCT01185132 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: accelerated partial breast irradiation - 3D-conformal planning
Description: 38.5 Gy, 10 fractions over 5 days
Study NCT01185132 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: accelerated partial breast irradiation - IMRT planning
Description: 38.5 Gy, 10 fractions over 5 days
Study NCT01689714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study NCT00305032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric balloon insertion
Description: patient would be offered endoscopic gastric balloon insertion
Study NCT00951080 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional NPWT System
Description: Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
Study NCT00951080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Wound Care System
Description: Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
Study NCT04562402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: cataract surgery via phacoemulsification
Study NCT04562402 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyclophotocoagulation
Description: Endoscopic ablation of the ciliary body
Study NCT01960998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
Study NCT01960998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Care and Wetness Management
Description: Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
Study NCT01960998 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Care and Wetness Management
Description: Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
Study NCT00790166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + ThermoSmart™ humidity
Description: an absolute humidity (AH) of 28 mg/l +/- 2mg/l
Study NCT00790166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + Conventional humidity
Description: an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
Study NCT00790166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP + No added humidity
Description: ambient humidity
Study NCT00759356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate sustained-release capsules
Description: 1 x 200 mg, single-dose capsule
Study NCT00759356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN
Description: 2 x 100 mg, single-dose capsule
Study NCT00704483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
Study NCT00704483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 0.8 g tid
Study NCT00704483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: 1.5 g tid
Study NCT00704483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer HCl
Description: 1.6 g tid
Study NCT03199053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
Study NCT02417701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02417701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02417701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT02638727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Citrulline
Description: This group treat with L-Citrulline (3 grams per day)
Study NCT02638727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: This group treat with placebo dayley
Study NCT01090960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0068
Description: Oral repeating dose
Study NCT01636804 — intervention group
Intervention type: DEVICE
Intervention: Quicksite
Description: St. Jude Medical produced lead called Quicksite
Study NCT01636804 — intervention group
Intervention type: DEVICE
Intervention: Quickflex
Description: St. Jude Medical produced lead called Quickflex
Study NCT03107754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Study NCT03107754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine-Sodium Bicarbonate
Description: Paracervical block will be injected at 2 points at the cervicovaginal junction to decrease pain
Study NCT03498300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Description: A single dose of Tdap vaccine at GA 27 - 36 weeks
Study NCT02563353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole-body vibration
Description: Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week.
Study NCT02563353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: Teriparatide, 20 microgram/day. 24 months of treatment.
Study NCT02563353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: Teriparatide, 20 microgram/day. 24 months of treatment.
Study NCT03199053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
Study NCT03199053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily